


which is involved in CRC development because it mediates inflammatory signaling pathways and can therefore be an important target for chemoprevention (Figure 2) [100].

### **7. Prevention of Obesity-Related HCC via the Nutraceutical Approach—BCAA and GTCs Effectively Prevent Obesity-Related Liver Carcinogenesis**

In addition to established risk factors such as hepatitis and alcohol consumption, obesity and its related metabolic abnormalities increase the risk of HCC [6–8,11]. NASH is also an important pathological condition when considering the prevention of obesity-related HCC because it progresses to cirrhosis and finally develops into HCC [53,54]. In order to elucidate the pathogenesis of obesity- and NASH-associated HCC and evaluate the mechanisms of how chemopreventive agents suppress these diseases, we developed a useful preclinical model using *db/db* mice and a liver carcinogen *N*-diethylnitrosamine (DEN) [101]. We found that *db/db* mice, which have severe steatosis, are more susceptible to DEN-induced liver tumorigenesis than the genetic control mice, and this oncogenic sensitivity is associated with the activation of the IGF/IGF-1R axis and induction of chronic inflammation in the liver [13,101–103].

Using this experimental model, we also investigated the possible inhibitory effects of BCAA and EGCG on obesity-related liver tumorigenesis. We found that BCAA supplementation significantly suppressed the development of hepatic preneoplastic lesions, known as foci of cellular alteration (FCA), in obese and diabetic *db/db* mice by inhibiting the expression of IGF-1, IGF-2, and IGF-1R in the liver [101]. The development of liver neoplasms, including hepatic adenoma and HCC, was also reduced by BCAA supplementation and this was associated with improvement of insulin resistance, reduction of serum levels of leptin, and attenuation of hepatic steatosis and fibrosis [101]. Yoshiji *et al.* [104] also reported that the chemopreventive effect exerted by BCAA supplementation against HCC in obese and diabetic rats was associated with the suppression of vascular endothelial growth factor expression and hepatic neovascularization. In addition, drinking water containing EGCG significantly inhibited the development of FCA and hepatic adenoma, and improved hepatic steatosis [103]. The serum levels of insulin, IGF-1, and IGF-2 and the phosphorylation of the IGF-1R, ERK, Akt, and GSK-3 $\beta$  proteins in the liver were reduced by EGCG consumption [103]. EGCG also decreased the levels of free fatty acids and TNF- $\alpha$  in the serum and the expression of TNF- $\alpha$ , IL-6, IL-1 $\beta$ , and IL-18 mRNAs in the liver, indicating that it prevents obesity-related liver tumorigenesis by inhibiting the IGF/IGF-1R axis, improving hyperinsulinemia, and attenuating chronic inflammation [103]. Thus, both BCAA and GTCs may be useful for the chemoprevention of liver carcinogenesis in obese individuals (Figure 3).

**Figure 3.** Mechanisms of action of GTCs and BCAA in the inhibition of obesity-related liver carcinogenesis.



## 8. Conclusions

In the present social and medical circumstances, the consequences of obesity and its related metabolic abnormalities, including cancer, are critical issues that need to be resolved. Among human cancers, CRC and HCC are the most representative malignancies affected by obesity. In this review, we indicate the possibility that the nutraceutical approach for targeting and restoring metabolic homeostasis may be a promising strategy to prevent the development of obesity-related CRC and HCC. Tea catechins, especially GTCs, are considered one of the most practical agents for the prevention of obesity-related carcinogenesis because the safety and efficacy of GTCs as chemopreventive agents have been demonstrated in recent interventional trials [69,71]. BCAA is also a feasible agent because its preparations are widely used in clinical practice for patients with chronic liver diseases, and a randomized controlled trial has shown that BCAA supplementation can prevent HCC in such patients who are obese [8,20]. Thus, active intervention using GTCs and BCAA might be an effective approach for the chemoprevention of obesity-related CRC and HCC.

## Acknowledgments

This review was based on studies supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (No. 22790638 to M.S. and No. 21590838 to H.M.)

and by Grant-in-Aid for the 3rd Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan.

### Conflict of Interest

The authors declare no conflict of interest.

### References

1. WHO: World Health Organization Fact Sheet for World Wide Prevalence of Obesity. Available online: <http://www.who.int/mediacentre/factsheets/fs311/en/indexhtml> (accessed on 27 December 2011).
2. Calle, E.E.; Kaaks, R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. *Nat. Rev. Cancer* **2004**, *4*, 579–591.
3. Anderson, A.S.; Caswell, S. Obesity management—An opportunity for cancer prevention. *Surgeon* **2009**, *7*, 282–285.
4. Giovannucci, E.; Michaud, D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. *Gastroenterology* **2007**, *132*, 2208–2225.
5. Frezza, E.E.; Wachtel, M.S.; Chiriva-Internati, M. Influence of obesity on the risk of developing colon cancer. *Gut* **2006**, *55*, 285–291.
6. El-Serag, H.B.; Rudolph, K.L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. *Gastroenterology* **2007**, *132*, 2557–2576.
7. El-Serag, H.B.; Tran, T.; Everhart, J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* **2004**, *126*, 460–468.
8. Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; *et al.* Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. *Hepatol. Res.* **2006**, *35*, 204–214.
9. World Cancer Research Fund/American Institute for Cancer Research. *Food, Nutrition, Physical activity, and the Prevention of Cancer: A Global Perspective 2007*; AICR: Washington, DC, USA, 2007.
10. Renehan, A.G.; Tyson, M.; Egger, M.; Heller, R.F.; Zwahlen, M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. *Lancet* **2008**, *371*, 569–578.
11. Calle, E.E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N. Engl. J. Med.* **2003**, *348*, 1625–1638.
12. Yasuda, Y.; Shimizu, M.; Shirakami, Y.; Sakai, H.; Kubota, M.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-*db/db* obese mice. *Cancer Sci.* **2010**, *101*, 1701–1707.

13. Shimizu, M.; Yasuda, Y.; Sakai, H.; Kubota, M.; Terakura, D.; Baba, A.; Ohno, T.; Kochi, T.; Tsurumi, H.; Tanaka, T.; *et al.* Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-*db/db* obese mice. *BMC Cancer* **2011**, *11*, doi: 10.1186/1471-2407-11-281.
14. Kubota, M.; Shimizu, M.; Sakai, H.; Yasuda, Y.; Ohno, T.; Kochi, T.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-*db/db* obese mice. *Biochem. Biophys. Res. Commun.* **2011**, *410*, 108–113.
15. Kao, Y.H.; Chang, H.H.; Lee, M.J.; Chen, C.L. Tea, obesity, and diabetes. *Mol. Nutr. Food Res.* **2006**, *50*, 188–210.
16. Yang, C.S.; Wang, X.; Lu, G.; Picinich, S.C. Cancer prevention by tea: Animal studies, molecular mechanisms and human relevance. *Nat. Rev. Cancer* **2009**, *9*, 429–439.
17. Shimizu, M.; Shirakami, Y.; Moriwaki, H. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. *Int. J. Mol. Sci.* **2008**, *9*, 1034–1049.
18. Shimizu, M.; Adachi, S.; Masuda, M.; Kozawa, O.; Moriwaki, H. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. *Mol. Nutr. Food Res.* **2011**, *55*, 832–843.
19. Shimizu, M.; Weinstein, I.B. Modulation of signal transduction by tea catechins and related phytochemicals. *Mutat. Res.* **2005**, *591*, 147–160.
20. Muto, Y.; Sato, S.; Watanabe, A.; Moriwaki, H.; Suzuki, K.; Kato, A.; Kato, M.; Nakamura, T.; Higuchi, K.; Nishiguchi, S.; *et al.* Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. *Clin. Gastroenterol. Hepatol.* **2005**, *3*, 705–713.
21. Marchesini, G.; Bianchi, G.; Merli, M.; Amodio, P.; Panella, C.; Loguercio, C.; Fanelli, F.R.; Abbiati, R.; Italian BCAA Study Group. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind, randomized trial. *Gastroenterology* **2003**, *124*, 1792–1801.
22. Kawaguchi, T.; Nagao, Y.; Matsuoka, H.; Ide, T.; Sata, M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. *Int. J. Mol. Med.* **2008**, *22*, 105–112.
23. Chang, C.K.; Ulrich, C.M. Hyperinsulinaemia and hyperglycaemia: Possible risk factors of colorectal cancer among diabetic patients. *Diabetologia* **2003**, *46*, 595–607.
24. Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. *Nat. Rev. Cancer* **2008**, *8*, 915–928.
25. Clayton, P.E.; Banerjee, I.; Murray, P.G.; Renehan, A.G. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. *Nat. Rev. Endocrinol.* **2011**, *7*, 11–24.
26. Bjork, J.; Nilsson, J.; Hultcrantz, R.; Johansson, C. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. *Scand. J. Gastroenterol.* **1993**, *28*, 879–884.
27. Tran, T.T.; Medline, A.; Bruce, W.R. Insulin promotion of colon tumors in rats. *Cancer Epidemiol. Biomark. Prev.* **1996**, *5*, 1013–1015.

28. Singh, P.; Rubin, N. Insulinlike growth factors and binding proteins in colon cancer. *Gastroenterology* **1993**, *105*, 1218–1237.
29. Kajantie, E.; Fall, C.H.; Seppala, M.; Koistinen, R.; Dunkel, L.; Yliharsila, H.; Osmond, C.; Andersson, S.; Barker, D.J.; Forsen, T.; *et al.* Serum insulin-like growth factor (IGF)-I and IGF-binding protein-1 in elderly people: Relationships with cardiovascular risk factors, body composition, size at birth, and childhood growth. *J. Clin. Endocrinol. Metab.* **2003**, *88*, 1059–1065.
30. Esposito, K.; Nappo, F.; Marfella, R.; Giugliano, G.; Giugliano, F.; Ciotola, M.; Quagliaro, L.; Ceriello, A.; Giugliano, D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. *Circulation* **2002**, *106*, 2067–2072.
31. Hotamisligil, G.S.; Shargill, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. *Science* **1993**, *259*, 87–91.
32. Hotamisligil, G.S.; Peraldi, P.; Budavari, A.; Ellis, R.; White, M.F.; Spiegelman, B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. *Science* **1996**, *271*, 665–668.
33. Kern, P.A.; Ranganathan, S.; Li, C.; Wood, L.; Ranganathan, G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. *Am. J. Physiol. Endocrinol. Metab.* **2001**, *280*, E745–E751.
34. Szlosarek, P.; Charles, K.A.; Balkwill, F.R. Tumour necrosis factor-alpha as a tumour promoter. *Eur. J. Cancer* **2006**, *42*, 745–750.
35. Valko, M.; Izakovic, M.; Mazur, M.; Rhodes, C.J.; Telser, J. Role of oxygen radicals in DNA damage and cancer incidence. *Mol. Cell. Biochem.* **2004**, *266*, 37–56.
36. Leslie, N.R. The redox regulation of PI 3-kinase-dependent signaling. *Antioxid. Redox Signal.* **2006**, *8*, 1765–1774.
37. Considine, R.V.; Sinha, M.K.; Heiman, M.L.; Kriauciunas, A.; Stephens, T.W.; Nyce, M.R.; Ohannesian, J.P.; Marco, C.C.; McKee, L.J.; Bauer, T.L.; *et al.* Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N. Engl. J. Med.* **1996**, *334*, 292–295.
38. Barb, D.; Williams, C.J.; Neuwirth, A.K.; Mantzoros, C.S. Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. *Am. J. Clin. Nutr.* **2007**, *86*, s858–s866.
39. Amemori, S.; Ootani, A.; Aoki, S.; Fujise, T.; Shimoda, R.; Kakimoto, T.; Shiraishi, R.; Sakata, Y.; Tsunada, S.; Iwakiri, R.; *et al.* Adipocytes and preadipocytes promote the proliferation of colon cancer cells *in vitro*. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2007**, *292*, G923–G929.
40. Stattin, P.; Lukanova, A.; Biessy, C.; Soderberg, S.; Palmqvist, R.; Kaaks, R.; Olsson, T.; Jellum, E. Obesity and colon cancer: Does leptin provide a link? *Int. J. Cancer* **2004**, *109*, 149–152.
41. Faggioni, R.; Feingold, K.R.; Grunfeld, C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. *FASEB J.* **2001**, *15*, 2565–2571.
42. Molina, A.; Vendrell, J.; Gutierrez, C.; Simon, I.; Masdevall, C.; Soler, J.; Gomez, J.M. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. *Obes. Surg.* **2003**, *13*, 615–621.
43. Fenton, J.I.; Hursting, S.D.; Perkins, S.N.; Hord, N.G. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc<sup>Min/+</sup> colon epithelial cell line. *Carcinogenesis* **2006**, *27*, 1507–1515.

44. Kang, S.; Song, J.; Kang, H.; Kim, S.; Lee, Y.; Park, D. Insulin can block apoptosis by decreasing oxidative stress via phosphatidylinositol 3-kinase- and extracellular signal-regulated protein kinase-dependent signaling pathways in HepG2 cells. *Eur. J. Endocrinol.* **2003**, *148*, 147–155.
45. Tornkvist, A.; Parpal, S.; Gustavsson, J.; Stralfors, P. Inhibition of Raf-1 kinase expression abolishes insulin stimulation of DNA synthesis in H4IIE hepatoma cells. *J. Biol. Chem.* **1994**, *269*, 13919–13921.
46. Imai, K.; Takai, K.; Nishigaki, Y.; Shimizu, S.; Naiki, T.; Hayashi, H.; Uematsu, T.; Sugihara, J.; Tomita, E.; Shimizu, M.; *et al.* Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. *Hepatol. Res.* **2010**, *40*, 376–382.
47. Powell, E.E.; Jonsson, J.R.; Clouston, A.D. Steatosis: Co-factor in other liver diseases. *Hepatology* **2005**, *42*, 5–13.
48. Alexia, C.; Fallot, G.; Lasfer, M.; Schweizer-Groyer, G.; Groyer, A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. *Biochem. Pharmacol.* **2004**, *68*, 1003–1015.
49. Shimizu, M.; Shirakami, Y.; Sakai, H.; Tatebe, H.; Nakagawa, T.; Hara, Y.; Weinstein, I.B.; Moriwaki, H. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. *Cancer Lett.* **2008**, *262*, 10–18.
50. Chen, C.; Chang, Y.C.; Liu, C.L.; Liu, T.P.; Chang, K.J.; Guo, I.C. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. *Endocr. Relat. Cancer* **2007**, *14*, 513–529.
51. Watanabe, N.; Takai, K.; Imai, K.; Shimizu, M.; Naiki, T.; Nagaki, M.; Moriwaki, H. Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment. *J. Clin. Biochem. Nutr.* **2011**, *49*, 153–158.
52. Angulo, P. Nonalcoholic fatty liver disease. *N. Engl. J. Med.* **2002**, *346*, 1221–1231.
53. Siegel, A.B.; Zhu, A.X. Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link. *Cancer* **2009**, *115*, 5651–5661.
54. Ratziu, V.; Bonyhay, L.; Di Martino, V.; Charlotte, F.; Cavallaro, L.; Sayegh-Tainturier, M.H.; Giral, P.; Grimaldi, A.; Opolon, P.; Poynard, T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. *Hepatology* **2002**, *35*, 1485–1493.
55. Day, C.P.; James, O.F. Steatohepatitis: A tale of two “hits”? *Gastroenterology* **1998**, *114*, 842–845.
56. Chitturi, S.; Abeygunasekera, S.; Farrell, G.C.; Holmes-Walker, J.; Hui, J.M.; Fung, C.; Karim, R.; Lin, R.; Samarasinghe, D.; Liddle, C.; *et al.* NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. *Hepatology* **2002**, *35*, 373–379.
57. Feldstein, A.E.; Werneburg, N.W.; Canbay, A.; Guicciardi, M.E.; Bronk, S.F.; Rydzewski, R.; Burgart, L.J.; Gores, G.J. Free fatty acids promote hepatic lipotoxicity by stimulating TNF- $\alpha$  expression via a lysosomal pathway. *Hepatology* **2004**, *40*, 185–194.

58. Crespo, J.; Cayon, A.; Fernandez-Gil, P.; Hernandez-Guerra, M.; Mayorga, M.; Dominguez-Diez, A.; Fernandez-Escalante, J.C.; Pons-Romero, F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. *Hepatology* **2001**, *34*, 1158–1163.
59. Chitturi, S.; Farrell, G.; Frost, L.; Kriketos, A.; Lin, R.; Fung, C.; Liddle, C.; Samarasinghe, D.; George, J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity? *Hepatology* **2002**, *36*, 403–409.
60. Wong, V.W.; Wong, G.L.; Tsang, S.W.; Fan, T.; Chu, W.C.; Woo, J.; Chan, A.W.; Choi, P.C.; Chim, A.M.; Lau, J.Y.; *et al.* High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. *Gut* **2011**, *60*, 829–836.
61. Hursel, R.; Viechtbauer, W.; Westerterp-Plantenga, M.S. The effects of green tea on weight loss and weight maintenance: A meta-analysis. *Int. J. Obes.* **2009**, *33*, 956–961.
62. Rains, T.M.; Agarwal, S.; Maki, K.C. Antiobesity effects of green tea catechins: A mechanistic review. *J. Nutr. Biochem.* **2011**, *22*, 1–7.
63. Grove, K.A.; Lambert, J.D. Laboratory, epidemiological, and human intervention studies show that tea (*Camellia sinensis*) may be useful in the prevention of obesity. *J. Nutr.* **2010**, *140*, 446–453.
64. Thielecke, F.; Boschmann, M. The potential role of green tea catechins in the prevention of the metabolic syndrome—A review. *Phytochemistry* **2009**, *70*, 11–24.
65. Ramadan, G.; El-Beih, N.M.; El-Ghffar, E.A.A. Modulatory effects of black *v.* green tea aqueous extract on hyperglycaemia, hyperlipidaemia and liver dysfunction in diabetic and obese rat models. *Br. J. Nutr.* **2009**, *102*, 1611–1619.
66. Murase, T.; Nagasawa, A.; Suzuki, J.; Hase, T.; Tokimitsu, I. Beneficial effects of tea catechins on diet-induced obesity: Stimulation of lipid catabolism in the liver. *Int. J. Obes.* **2002**, *26*, 1459–1464.
67. Bose, M.; Lambert, J.D.; Ju, J.; Reuhl, K.R.; Shapses, S.A.; Yang, C.S. The major green tea polyphenol, (–)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. *J. Nutr.* **2008**, *138*, 1677–1683.
68. Qin, B.; Polansky, M.M.; Harry, D.; Anderson, R.A. Green tea polyphenols improve cardiac muscle mRNA and protein levels of signal pathways related to insulin and lipid metabolism and inflammation in insulin-resistant rats. *Mol. Nutr. Food Res.* **2010**, *54*, S14–S23.
69. Bettuzzi, S.; Brausi, M.; Rizzi, F.; Castagnetti, G.; Peracchia, G.; Corti, A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. *Cancer Res.* **2006**, *66*, 1234–1240.
70. Li, N.; Sun, Z.; Han, C.; Chen, J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. *Proc. Soc. Exp. Biol. Med.* **1999**, *220*, 218–224.
71. Shimizu, M.; Fukutomi, Y.; Ninomiya, M.; Nagura, K.; Kato, T.; Araki, H.; Suganuma, M.; Fujiki, H.; Moriwaki, H. Green tea extracts for the prevention of metachronous colorectal adenomas: A pilot study. *Cancer Epidemiol. Biomark. Prev.* **2008**, *17*, 3020–3025.

72. Shirakami, Y.; Shimizu, M.; Tsurumi, H.; Hara, Y.; Tanaka, T.; Moriwaki, H. EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. *Mol. Med. Rep.* **2008**, *1*, 355–361.
73. Adachi, S.; Nagao, T.; Ingolfsson, H.I.; Maxfield, F.R.; Andersen, O.S.; Kopelovich, L.; Weinstein, I.B. The inhibitory effect of (–)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. *Cancer Res.* **2007**, *67*, 6493–6501.
74. Adachi, S.; Nagao, T.; To, S.; Joe, A.K.; Shimizu, M.; Matsushima-Nishiwaki, R.; Kozawa, O.; Moriwaki, H.; Maxfield, F.R.; Weinstein, I.B. (–)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. *Carcinogenesis* **2008**, *29*, 1986–1993.
75. Shimizu, M.; Deguchi, A.; Hara, Y.; Moriwaki, H.; Weinstein, I.B. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. *Biochem. Biophys. Res. Commun.* **2005**, *334*, 947–953.
76. Yasuda, Y.; Shimizu, M.; Sakai, H.; Iwasa, J.; Kubota, M.; Adachi, S.; Osawa, Y.; Tsurumi, H.; Hara, Y.; Moriwaki, H. (–)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R. *Chem. Biol. Interact.* **2009**, *182*, 159–164.
77. Moriwaki, H.; Miwa, Y.; Tajika, M.; Kato, M.; Fukushima, H.; Shiraki, M. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis. *Biochem. Biophys. Res. Commun.* **2004**, *313*, 405–409.
78. Kawaguchi, T.; Izumi, N.; Charlton, M.R.; Sata, M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. *Hepatology* **2011**, *54*, 1063–1070.
79. Petrides, A.S.; Vogt, C.; Schulze-Berge, D.; Matthews, D.; Strohmeyer, G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. *Hepatology* **1994**, *19*, 616–627.
80. Mehta, S.H.; Brancati, F.L.; Sulkowski, M.S.; Strathdee, S.A.; Szklo, M.; Thomas, D.L. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Ann. Intern. Med.* **2000**, *133*, 592–599.
81. She, P.; Reid, T.M.; Bronson, S.K.; Vary, T.C.; Hajnal, A.; Lynch, C.J.; Hutson, S.M. Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. *Cell Metab.* **2007**, *6*, 181–194.
82. Zhang, Y.; Guo, K.; LeBlanc, R.E.; Loh, D.; Schwartz, G.J.; Yu, Y.H. Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. *Diabetes* **2007**, *56*, 1647–1654.
83. Ikehara, O.; Kawasaki, N.; Maezono, K.; Komatsu, M.; Konishi, A. Acute and chronic treatment of L-isoleucine ameliorates glucose metabolism in glucose-intolerant and diabetic mice. *Biol. Pharm. Bull.* **2008**, *31*, 469–472.
84. Higuchi, N.; Kato, M.; Miyazaki, M.; Tanaka, M.; Kohjima, M.; Ito, T.; Nakamuta, M.; Enjoji, M.; Kotoh, K.; Takayanagi, R. Potential role of branched-chain amino acids in glucose metabolism through the accelerated induction of the glucose-sensing apparatus in the liver. *J. Cell. Biochem.* **2011**, *112*, 30–38.

85. Hinault, C.; Mothe-Satney, I.; Gautier, N.; Lawrence, J.C., Jr.; van Obberghen, E. Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from *db/db* mice. *FASEB J.* **2004**, *18*, 1894–1896.
86. Nishitani, S.; Takehana, K.; Fujitani, S.; Sonaka, I. Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2005**, *288*, G1292–G1300.
87. Arakawa, M.; Masaki, T.; Nishimura, J.; Seike, M.; Yoshimatsu, H. The effects of branched-chain amino acid granules on the accumulation of tissue triglycerides and uncoupling proteins in diet-induced obese mice. *Endocr. J.* **2011**, *58*, 161–170.
88. Nishimura, J.; Masaki, T.; Arakawa, M.; Seike, M.; Yoshimatsu, H. Isoleucine prevents the accumulation of tissue triglycerides and upregulates the expression of PPARalpha and uncoupling protein in diet-induced obese mice. *J. Nutr.* **2010**, *140*, 496–500.
89. Sakaida, I.; Tsuchiya, M.; Okamoto, M.; Okita, K. Late evening snack and the change of blood glucose level in patients with liver cirrhosis. *Hepatol. Res.* **2004**, *30*, 67–72.
90. Urata, Y.; Okita, K.; Korenaga, K.; Uchida, K.; Yamasaki, T.; Sakaida, I. The effect of supplementation with branched-chain amino acids in patients with liver cirrhosis. *Hepatol. Res.* **2007**, *37*, 510–516.
91. Hagiwara, A.; Nishiyama, M.; Ishizaki, S. Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. *J. Cell. Physiol.* **2011**, doi: 10.1002/jcp.22941.
92. Forte, A.; de Sanctis, R.; Leonetti, G.; Manfredelli, S.; Urbano, V.; Bezzi, M. Dietary chemoprevention of colorectal cancer. *Ann. Ital. Chir.* **2008**, *79*, 261–267.
93. Hirose, Y.; Hata, K.; Kuno, T.; Yoshida, K.; Sakata, K.; Yamada, Y.; Tanaka, T.; Reddy, B.S.; Mori, H. Enhancement of development of azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-*db/db* mice. *Carcinogenesis* **2004**, *25*, 821–825.
94. Lee, G.H.; Proenca, R.; Montez, J.M.; Carroll, K.M.; Darvishzadeh, J.G.; Lee, J.I.; Friedman, J.M. Abnormal splicing of the leptin receptor in diabetic mice. *Nature* **1996**, *379*, 632–635.
95. Shimizu, M.; Shirakami, Y.; Sakai, H.; Adachi, S.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-*db/db* mice. *Cancer Prev. Res.* **2008**, *1*, 298–304.
96. Suzuki, R.; Kohno, H.; Yasui, Y.; Hata, K.; Sugie, S.; Miyamoto, S.; Sugawara, K.; Sumida, T.; Hirose, Y.; Tanaka, T. Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male *db/db* mice. *Int. J. Cancer* **2007**, *120*, 252–258.
97. Hayashi, K.; Suzuki, R.; Miyamoto, S.; Shin-Ichiroh, Y.; Kohno, H.; Sugie, S.; Takashima, S.; Tanaka, T. Citrus auraptene suppresses azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-*db/db* mice. *Nutr. Cancer* **2007**, *58*, 75–84.
98. Miyamoto, S.; Yasui, Y.; Ohigashi, H.; Tanaka, T.; Murakami, A. Dietary flavonoids suppress azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-*db/db* mice. *Chem. Biol. Interact.* **2010**, *183*, 276–283.

99. Shimizu, M.; Shirakami, Y.; Iwasa, J.; Shiraki, M.; Yasuda, Y.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-*db/db* mice. *Clin. Cancer Res.* **2009**, *15*, 3068–3075.
100. Gupta, R.A.; Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. *Nat. Rev. Cancer* **2001**, *1*, 11–21.
101. Iwasa, J.; Shimizu, M.; Shiraki, M.; Shirakami, Y.; Sakai, H.; Terakura, Y.; Takai, K.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-*db/db* mice. *Cancer Sci.* **2010**, *101*, 460–467.
102. Shimizu, M.; Sakai, H.; Shirakami, Y.; Iwasa, J.; Yasuda, Y.; Kubota, M.; Takai, K.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J-*Lepr<sup>db</sup>/+Lepr<sup>db</sup>* mice. *Cancer Prev. Res.* **2011**, *4*, 128–136.
103. Shimizu, M.; Sakai, H.; Shirakami, Y.; Yasuda, Y.; Kubota, M.; Terakura, D.; Baba, A.; Ohno, T.; Hara, Y.; Tanaka, T.; *et al.* Preventive Effects of (–)-Epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-*db/db* mice. *Cancer Prev. Res.* **2011**, *4*, 396–403.
104. Yoshiji, H.; Noguchi, R.; Kitade, M.; Kaji, K.; Ikenaka, Y.; Namisaki, T.; Yoshii, J.; Yanase, K.; Yamazaki, M.; Tsujimoto, T.; *et al.* Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. *J. Gastroenterol.* **2009**, *44*, 483–491.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).



## Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand

Tomohiko Ohno, Yohei Shirakami, Masahito Shimizu\*, Masaya Kubota, Hiroyasu Sakai, Yoichi Yasuda, Takahiro Kochi, Hisashi Tsurumi, Hisataka Moriwaki

Department of Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan

### ARTICLE INFO

#### Article history:

Received 4 November 2011

Received in revised form 29 March 2012

Accepted 20 April 2012

#### Keywords:

Acyclic retinoid

GW4064

Hepatocellular carcinoma

RXR $\alpha$

FXR

Synergism

### ABSTRACT

Abnormalities in the expression and function of retinoid X receptor (RXR), a master regulator of the nuclear receptor superfamily, are associated with the development of hepatocellular carcinoma (HCC). Dysfunction of farnesoid X receptor (FXR), one of the nuclear receptors that forms a heterodimer with RXR, also plays a role in liver carcinogenesis. In the present study, we examined the effects of acyclic retinoid (ACR), a synthetic retinoid targeting RXR $\alpha$ , plus GW4064, a ligand for FXR, on the growth of human HCC cells. We found that ACR and GW4064 preferentially inhibited the growth of HLE, HLF, and Huh7 human HCC cells in comparison with Hc normal hepatocytes. The combination of 1  $\mu$ M ACR plus 1  $\mu$ M GW4064 synergistically inhibited the growth of HLE cells by inducing apoptosis. The combined treatment with these agents acted cooperatively to induce cell cycle arrest in the G<sub>0</sub>/G<sub>1</sub> phase and inhibit the phosphorylation of RXR $\alpha$ , which is regarded as a critical factor for liver carcinogenesis, through inhibition of ERK and Stat3 phosphorylation. This combination also increased the expression levels of p21<sup>CIP1</sup> and SHP mRNA, while decreasing the levels of c-myc and cyclin D1 mRNA in HLE cells. In addition, a reporter assay indicated that the FXRE promoter activity was significantly increased by treatment with ACR plus GW4064. Our results suggest that ACR and GW4064 cooperatively inhibit RXR $\alpha$  phosphorylation, modulate the expression of FXR-regulated genes, thus resulting in the induction of apoptosis and the inhibition of growth in HCC cells. This combination might therefore be effective for the chemoprevention and chemotherapy of HCC.

© 2012 Elsevier Ireland Ltd. All rights reserved.

### 1. Introduction

Nuclear receptors are ligand-dependent transcription factors that are involved in various physiological processes. Retinoid X receptors (RXRs) are regarded as master regulators of nuclear receptors because they play an essential role in controlling normal cell proliferation and metabolism by forming a heterodimer with other nuclear receptors [1,2]. Therefore, abnormalities in the

expression and function of RXRs are closely associated with the development of various disorders, including cancer, whereas using a retinoid might be an effective strategy for the prevention and treatment of human malignancies [3]. A malfunction of RXR $\alpha$ , one of the subtypes of RXR, due to phosphorylation by the Ras/MAPK signaling pathway is profoundly associated with liver carcinogenesis [4–8]. On the other hand, administration of acyclic retinoid (ACR), a synthetic retinoid which targets RXR $\alpha$ , reduced the incidence of post-therapeutic recurrence of hepatocellular carcinoma (HCC) and improved the survival rate of patients with this malignancy [9,10]. ACR also inhibits the growth of HCC-derived cells by inducing apoptosis and cell cycle arrest in the G<sub>0</sub>/G<sub>1</sub> phase [11,12]. These findings suggest that nuclear receptors, especially RXR $\alpha$ , are critical targets for the prevention and treatment of HCC.

Farnesoid X receptor (FXR), which has been characterized as a bile acid receptor, is also a member of the nuclear receptor superfamily of ligand-dependent transcription factors that form heterodimers with RXR [13]. FXR has been shown to be essential in controlling bile acid, lipid, and glucose homeostasis [13]. It also plays a critical role in normal liver regeneration and promotes liver repair after injury by mediating its related signaling pathways [14].

**Abbreviations:** ACR, acyclic retinoid; CI, combination index; DAPI, 4',6'-diamidino-2-phenylindole; ERK, extracellular signal-regulated kinase; FXR, farnesoid X receptor; FXRE, farnesoid X receptor response element; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HCC, hepatocellular carcinoma; IFN, interferon; MAPK, mitogen-activated protein kinase; PARP, poly (ADP-ribose) polymerase; RAR, retinoic acid receptor; RARE, retinoic acid response element; RTK, receptor tyrosine kinase; RT-PCR, reverse transcription PCR; RXR, retinoid X receptor; SHP, small heterodimer partner; Stat3, signal transducer and activator of transcription 3; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling.

\* Corresponding author. Address: Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan. Tel.: +81 58 230 6313; fax: +81 58 230 6310.

E-mail address: [shimim-gif@umin.ac.jp](mailto:shimim-gif@umin.ac.jp) (M. Shimizu).

0304-3835/\$ - see front matter © 2012 Elsevier Ireland Ltd. All rights reserved.  
<http://dx.doi.org/10.1016/j.canlet.2012.04.015>

In addition, recent studies have revealed that aberrations in FXR are involved in liver carcinogenesis. FXR deficiency in mice leads to the development of neoplasms in the liver, including hepatic adenoma, HCC, and hepatocolangiocellular carcinoma [15,16]. A significant decrease in FXR expression and activity is also observed in human HCC samples [17]. Therefore, targeting FXR and improving its function might be a promising strategy for the prevention and treatment of HCC.

Recently, combination therapy and prevention have garnered much interest in the cancer field because they can synergistically inhibit growth and induce apoptosis in cancer cells. In human HCC-derived cells, ACR acts synergistically with other agents, such as interferon (IFN)- $\beta$ , OSI-461, vitamin K<sub>2</sub>, valproic acid, and trastuzumab, in suppressing growth and inducing apoptosis [11,18–21]. The agents that inhibit RXR $\alpha$  phosphorylation are among the most promising agents to use in combination with ACR [11,20,21]. In addition, the induction of nuclear receptors that dimerize with RXR, such as retinoic acid receptor (RAR)- $\beta$ , and activation of these receptors by their ligands may also lead to synergistic growth inhibition in HCC cells when combined with ACR [11,19]. GW4064, a synthetic ligand for FXR, is known to induce the expression of genes involved in the transport of bile acids in the liver and intestines [22,23]. GW4064 also inhibits the growth of breast and prostate cancer cell lines [24–26], whereas the anti-cancer effects of this agent on HCC cells have not been evaluated. In the present study, we examined the effects of GW4064 on the growth of human HCC cells. We also investigated whether the combination of ACR plus GW4064 exerts synergistic growth inhibitory effects on HCC cells and examined the possible mechanisms responsible for such synergy.

## 2. Materials and methods

### 2.1. Materials

ACR (NIK-333) was supplied by Kowa Pharmaceutical Co. Ltd., (Tokyo, Japan). GW4064 was purchased from Sigma–Aldrich (St. Louis, MO, USA). The anti-RXR $\alpha$  antibody was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The primary antibodies for ERK, phosphorylated ERK (p-ERK), Stat3, phosphorylated Stat3 (p-Stat3), PARP, and GAPDH were from Cell Signaling Technology (Beverly, MA, USA).

### 2.2. Cell lines and cell culture conditions

HLE, HLF, and Huh7 human HCC cell lines were obtained from the Japanese Cancer Research Resources Bank (Tokyo, Japan). HLE and HLF cells were maintained in DMEM and Huh7 cells were in RPMI1640 media, respectively. All media were supplemented with 10% FCS and 1% Penicillin/Streptomycin. Hc human normal hepatocyte cell line was purchased from Cell Systems (Kirkland, WA, USA) and maintained in a CS-S complete medium (Cell Systems). These cells were cultured in an incubator with humidified air with 5% CO<sub>2</sub> at 37 °C.

### 2.3. Cell proliferation assays

One thousand of HCC (HLE, HLF, and Huh7) or Hc cells were seeded on 96-well plates. The following day, the medium was changed to serum free medium and the cells were treated with the indicated concentrations of ACR or GW4064 for 48 h. Cell proliferation assays were performed using a MTS assay (Promega, Madison, WI, USA) according to the manufacturer's instructions. To determine whether the combined effects of ACR plus GW4064 were synergistic, HCC cells were treated with combinations of the indicated concentrations of ACR and GW4064 for 48 h and the combination index (CI)-isobologram was calculated. Variable ratios of drug concentrations were used in the studies, and mutually exclusive equations were used to determine the CIs. Each CI was calculated from the mean affected fraction at each drug ratio concentration (triplicate), as described previously [11,19,27].

### 2.4. Apoptosis assays

TUNEL, caspase-3 activity, and Annexin V assays are conducted to evaluate apoptosis. For TUNEL assay, HLE cells ( $1 \times 10^6$ ) were treated with 1  $\mu$ M ACR alone, 1  $\mu$ M GW4064 alone, or the combination of these agents for 48 h on glass bottom culture dishes. The cells were then fixed with 4% paraformaldehyde at room temperature for 10 min, permeabilized with 0.3% Triton X-100 in TBS (pH 7.4), and

stained with both 4',6-diamidino-2-phenylindole (DAPI) and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) methods using the *In Situ* Cell Death Detection Kit, Fluorescein (Roche Diagnostics, Mannheim, Germany) [11].

Caspase-3 activity and Annexin V assays were performed using HLE cells that were treated with the same concentration of test drugs for 72 h. The cell lysates were prepared and the caspase-3 activity assay was done using the ApoAlert Caspase Fluorescent Assay Kit (Clontech Laboratories, Mountain View, CA, USA). The Annexin V-binding capacity of treated cells was investigated by flow cytometry using the Annexin V-FITC apoptosis detection kit I (BD, Franklin Lakes, NJ, USA). Cultured cells were washed with cold phosphate-buffered saline before incubation with Annexin V-FITC in a buffer containing propidium iodide (PI). Stained cells were analyzed by flow cytometry using the FACScan (BD). Annexin V-FITC-positive and PI negative cells were considered to be populations undergoing apoptosis.

### 2.5. Cell cycle assays

HLE cells were treated with 1  $\mu$ M ACR alone, 1  $\mu$ M GW4064 alone, or the combination of these agents for 72 h in DMEM medium with 1% FCS. The harvested cells were stained with PI using Cell Cycle Phase Determination Kit (Cayman, Ann Arbor, MI, USA), and the samples were then analyzed for DNA histograms and cell cycle phase distribution using a FACScan flow cytometer. The data were analyzed by using the CellQuest computer program (BD) [11].

### 2.6. Protein extraction and Western blot analysis

Equivalent amounts of extracted protein were examined by a Western blot analysis using specific antibodies [21]. To detect the expression level of phosphorylated RXR $\alpha$  (p-RXR $\alpha$ ) protein, total phosphoprotein was affinity-purified from the total cell extracts using a PhosphoProtein Purification Column (QIAGEN, Valencia, CA, USA) and then was subjected to the Western blot analyses using an anti-RXR $\alpha$  antibody. GAPDH expression served as a loading control. The intensities of protein bands were quantified using NIH image software version 1.45.

### 2.7. RNA extraction and quantitative RT-PCR analysis

Total RNA was isolated from the HLE cells using the RNAqueous-4PCR kit (Ambion Applied Biosystems, Austin, TX, USA) and cDNA was amplified from 0.2  $\mu$ g of total RNA using the SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA) [28]. Quantitative real-time reverse transcription-PCR (RT-PCR) analysis was performed using specific primers that amplify the *c-myc*, small heterodimer partner (SHP), p21<sup>CIP1</sup>, cyclin D1, and  $\beta$ -actin genes. The specific primer sets for p21<sup>CIP1</sup>, cyclin D1, and  $\beta$ -actin were used as described elsewhere [12,29]. The sequences for *c-myc*- and SHP-specific primers were as follows: FMYC (5'-CCC TGA GCG ATT CAG ATG AT-3') and RMYC (5'-GCT CCA GGA TGT TGT GGT TT-3'), and FSHP (5'-GCT GTC TGG AGT CCT TCT GG-3') and RSHP (5'-ACC TGA GCA AAA GCA TGT CC-3'), respectively.

### 2.8. FXRE reporter assays

HLE cells were transfected with FXR response element (FXRE) reporter plasmids (100 ng/well in 96-well dish), which were kindly provided by Dr. T. Nishimaki-Mogami (National Institute of Health Sciences, Tokyo, Japan), along with pRL-CMV (*Renilla* luciferase, 10 ng/well in 96-well dish; Promega) as an internal standard to normalize the transfection efficiency. Transfections were done using Lipofectamine LTX Reagent (Invitrogen). After exposure of the cells to the transfection mixture for 24 h, the cells were treated with 1  $\mu$ M ACR alone, 1  $\mu$ M GW4064 alone, or the combination of these agents for 24 h. The cell lysates were then prepared, and the luciferase activity of each cell lysate was determined using a dual-luciferase reporter assay system (Promega) [11].

### 2.9. Statistical analysis

The data are expressed as the means  $\pm$  SD. Statistical significance of the differences in the mean values was assessed with a one-way ANOVA, followed by Tukey–Kramer's multiple comparison tests. Values of  $P < 0.05$  were considered to be significant.

## 3. Results

### 3.1. ACR and GW4064 cause preferential inhibition of the growth of human HCC cells in comparison with Hc normal hepatocytes

In our initial study, we examined the growth inhibitory effect of ACR and GW4064 on HLE, HLF, and Huh7 human HCC cells and on Hc hepatocytes. ACR inhibited the growth of HCC cells with an IC<sub>50</sub> value of less than 4  $\mu$ M. The HLF cells were most susceptible to ACR

because the  $IC_{50}$  value with this agent was 2  $\mu$ M (Fig. 1A). GW4064 also inhibited the growth of this series of HCC cells with an  $IC_{50}$  value of about 1.4  $\mu$ M (Fig. 1B). On the other hand, Hc cells were resistant to these agents up to 5  $\mu$ M (Fig. 1). These results suggest that ACR and GW4064 preferentially inhibit the growth of HCC cells compared with that of normal hepatocytes.

### 3.2. ACR plus GW4064 cause synergistic inhibition of the growth of HCC cells

Next, the effects of combined treatment were examined with a range of concentrations of ACR plus GW4064 to determine whether they synergistically inhibited the growth of HLE (Fig. 2A), HLF (Fig. 2B), and Huh7 (Fig. 2C) HCC cells. We found that the CI indices for less than 1  $\mu$ M ACR (0.5 or 1  $\mu$ M) plus less than 0.5  $\mu$ M GW4064 (0.1 or 0.5  $\mu$ M) were 1+(slight synergism), 2+(moderate synergism), or 3+(synergism), respectively, in this series of HCC cells (Fig. 2D and Table 1). These findings suggest that ACR plus GW4064 might be an effective combination for the inhibition of HCC cell growth due to their synergistic activity. The combination of 1  $\mu$ M ACR (about  $IC_{25}$  value) and 1  $\mu$ M GW4064 (about  $IC_{30}$  value) in HLE cells (Fig. 2A and D, and Table 1) was used for the following experiments because a CI-isobologram analysis gave this combination a CI index of 1+(0.88), indicating slight synergism.

### 3.3. ACR plus GW4064 cooperatively induce apoptosis in HLE cells

We next examined whether the synergistic growth inhibition in HLE cells induced by treatment with ACR plus GW4064 might be associated with the induction of apoptosis. In TUNEL assays, the treatment of HLE cells with either 1  $\mu$ M ACR or 1  $\mu$ M GW4064 alone induced TUNEL-positive cells in approximately 19.3% or 11.9% of the total viable cells, respectively. However, the combination of these agents markedly enhanced the induction of apoptosis, with 51.6% of the total viable cells being TUNEL-positive (Fig. 3A). Similar results were also observed in the Western blot analysis for PARP expression; the combination of ACR plus GW4064 markedly enhanced PARP cleavage, indicating the induction of apoptosis (Fig. 3B). We also found an increase in the levels of caspase-3 activity in ACR alone- and GW4064 alone-treated cells, and this was significantly enhanced when the cells were treated with a combination of these agents (Fig. 3C). In addition, the percentage of Annexin V-positive cells, which was increased by treatment with GW4064 alone, was substantially increased by the combined treatment with ACR plus GW4064 (Fig. 3D). These findings suggest that the combination with ACR plus GW4064 synergistically inhibited

growth of HLE human HCC cells, mainly, through the induction of apoptosis.

### 3.4. ACR plus GW4064 cooperatively induce $G_0/G_1$ cell cycle arrest in HLE cells


A cell cycle analysis was performed using DNA flow cytometry to determine whether the synergistic effects on growth inhibition caused by combined treatment with ACR plus GW4064 were associated with specific changes in cell cycle distribution. As shown in Fig. 4, the combined treatment with 1  $\mu$ M ACR plus 1  $\mu$ M GW4064 significantly increased the percentage of cells in the  $G_0/G_1$  phase in comparison to that of untreated cells ( $76.1 \pm 4.3\%$  vs.  $57.3 \pm 5.8\%$ ,  $P < 0.05$ ), whereas the population of cells in this phase was not significantly increased by treatment with ACR alone ( $63.6 \pm 3.0\%$ ) or GW4064 alone ( $65.3 \pm 4.5\%$ ). These findings suggest that the combination of ACR plus GW4064 cooperatively induced  $G_0/G_1$  phase cell cycle arrest in HLE human HCC cells.

### 3.5. ACR plus GW4064 additively suppress the phosphorylation of RXR $\alpha$ , ERK, and Stat3 proteins in HLE cells


RXR $\alpha$  phosphorylation plays a critical role in the development of HCC and might be a promising target for HCC chemoprevention [4–8]. Therefore, the effects of the combination of ACR plus GW4064 on the phosphorylation of this nuclear receptor and related signaling molecules were investigated in HLE cells. As shown in Fig. 5, when the cells were treated with 1  $\mu$ M ACR, there was a marked decrease in the expression levels of p-RXR $\alpha$  and p-Stat3 proteins. Treatment with 1  $\mu$ M GW4064 alone also decreased the expression levels of p-ERK and p-Stat3 protein. Moreover, the expression levels of p-RXR $\alpha$ , p-ERK and p-Stat3 proteins were markedly decreased when the cells were treated with the combination of these agents.

### 3.6. ACR plus GW4064 cooperatively affect the expression levels of p21<sup>CIP1</sup>, c-myc, cyclin D1, and SHP mRNA in HLE cells

We next examined the combined effects of ACR plus GW4064 on the expression levels of p21<sup>CIP1</sup>, c-myc, and cyclin D1 mRNA in HLE cells because these genes control cell proliferation and cell cycle progression. The quantitative RT-PCR analyses revealed that treatment with neither 1  $\mu$ M ACR nor 1  $\mu$ M GW4064 alone had any apparent effect on the expression levels of p21<sup>CIP1</sup>, c-myc, and cyclin D1 mRNA. However, when the cells were treated with the combination of these agents, there was a significant increase



**Fig. 1.** Inhibition of cell growth by ACR and GW4064 in HLE, HLF, and Huh7 human HCC cells and Hc normal hepatocytes. HLE, HLF, Huh7, and Hc cells were treated with the indicated concentrations of ACR (A) or GW4064 (B) for 48 h. Cell viability was determined by MTS assay and was expressed as a percentage of the control value. Error Bars, SD of triplicate assays.




**Fig. 2.** Inhibition of cell growth by ACR alone, GW4064 alone, and various combinations of these agents in HCC cells. HLE (A), HLF (B), and Huh7 (C) cells were treated with the indicated concentrations of ACR alone, GW4064 alone, and various combinations of these agents for 48 h. Cell viability was determined by MTS assay and expressed as a percentage of the control value. Error Bars, SD of triplicate assays. (D) The data obtained in (A), (B), and (C) was used to calculate the combination index.


**Table 1**  
Combined effects of ACR and GW4064 on HCC cells.

	HLE ACR concentration (μM)			HLF ACR concentration (μM)			HuH7 ACR concentration (μM)		
	0.5	1	2	0.5	1	2	0.5	1	2
GW4064 concentration (μM)									
0.1	+++	++	+	+++	+	±	+++	++	++
0.5	++	++	±	+++	++	±	++	+	±
1	±	+	±	+++	+	±	±	±	±

Note: "±", CI 0.9–1.1 additive effect; "+", CI 0.8–0.9 slight synergism; "++", CI 0.6–0.8 moderate synergism; "+++", CI 0.4–0.6 synergism; Abbreviations: CI, combination index; ACR, acyclic retinoid.



**Fig. 3.** Effects of the combination of ACR plus GW4064 on induction of apoptosis in HLE cells. The cells were treated with vehicle, 1  $\mu$ M ACR alone, 1  $\mu$ M GW4064 alone, or the combination of 1  $\mu$ M ACR plus 1  $\mu$ M GW4064 for 48 h or 72 h. TUNEL assays (A) and Western blot analysis using a PARP-specific antibody (B, upper panel) were performed using cells treated with test drugs for 48 h. Caspase-3 activity assays (C) and Annexin V assays (D) were performed using samples treated for 72 h. (A) TUNEL-positive cells were counted and examined as the percentage of the DAPI-positive cell number (500 cells were counted in each flask). (B) The intensities of the cleaved PARP (c-PARP) blots were quantified using densitometry. Columns and lines indicate mean and SD of triplicate assays (lower panel). (C) Caspase-3 activity was performed with a fluorometric system. (D) Cultured cells were incubated with Annexin V-FITC in a buffer containing propidium iodide (PI). Stained cells were then analyzed by flow cytometry. Annexin V-FITC-positive and PI-negative cells were counted as apoptotic cells. #:  $P < 0.05$ , compared with vehicle treated cells. ##:  $P < 0.05$ , compared with vehicle, ACR alone, or GW4064 alone treated cells.



**Fig. 4.** Effects of the combination of ACR plus GW4064 on induction of the G<sub>0</sub>/G<sub>1</sub> cell cycle arrest in HLE cells. HLE cells were treated with vehicle, 1  $\mu$ M ACR alone, 1  $\mu$ M GW4064 alone, or the combination of 1  $\mu$ M ACR plus 1  $\mu$ M GW4064 for 72 h. The cells were then stained with propidium iodide to analyze their cell cycle progression. The distributions of cells in the G<sub>0</sub>/G<sub>1</sub> of the cell cycle were calculated using a FACScan. Error Bars, SE of triplicate assays. #:  $P < 0.05$ , compared with vehicle treated cells.

in the levels p21<sup>CIP1</sup>, and a decrease in the levels of c-myc and cyclin D1 mRNA expression (Fig. 6A–C). In addition, the expression


level of SHP mRNA, which is one of the target genes of FXR [17,25,30,31], was also significantly increased by the combination treatment with ACR plus GW4064 (Fig. 6D).

**3.7. ACR enhances the induction of FXRE promoter activities by GW4064**


FXR and RXRs modulate the expression of target genes by interacting with FXRE elements located in the promoter regions of such genes [13]. Therefore, we next examined whether ACR might enhance the transcriptional activity of the FXRE promoter induced by GW4064 using transient transfection luciferase reporter assays. As shown in Fig. 6E, 1  $\mu$ M GW4064 significantly increased the FXRE reporter activity in comparison with control HLE cells which were not treated with either ACR or GW4064. Moreover, when the cells were treated with a combination of 1  $\mu$ M GW4064 plus 1  $\mu$ M ACR, there was a significant increase in the transcriptional activity of the FXRE reporter, thus suggesting that treatment with these agents might cooperatively enhance the FXRE reporter activity.

**4. Discussion**

The prognosis for patients with HCC is poor and more effective strategies for the chemoprevention and chemotherapy of this malignancy are urgently required. The present study provides the



**Fig. 5.** Effects of the combination of ACR plus GW4064 on the phosphorylation of RXR $\alpha$ , ERK, and Stat3 proteins in HLE cells. HLE cells were treated with vehicle, 1  $\mu$ M ACR alone, 1  $\mu$ M GW4064 alone, or the combination of 1  $\mu$ M ACR plus 1  $\mu$ M GW4064 for 12 h. The extracted proteins were examined by a Western blot analysis using the respective antibodies (left panels). The intensities of the blots were quantified using densitometry. Columns and lines indicate means and SD of triplicate assays (right panels). Repeat Western blots gave similar results. \*:  $P < 0.05$ , \$:  $P < 0.01$ , #:  $P < 0.001$ , compared with vehicle treated cells.




**Fig. 6.** Effects of the combination of ACR plus GW4064 on the expression of p21<sup>CIP1</sup>, *c-myc*, cyclin D1, and SHP mRNA and on the transcriptional activity of the FXRE promoter in HLE cells. HLE cells were treated with vehicle, 1  $\mu$ M ACR alone, 1  $\mu$ M GW4064 alone, or the combination of 1  $\mu$ M ACR plus 1  $\mu$ M GW4064 for 24 h. The extracted mRNAs were examined by a quantitative real-time RT-PCR analysis using the p21<sup>CIP1</sup> (A), *c-myc* (B), cyclin D1 (C), and SHP (D) specific primers. The expression levels of each mRNA were normalized to the level of  $\beta$ -actin mRNA. Values represent the means  $\pm$  SD of triplicate analyses. \*:  $P < 0.05$ . (E) A transient transfection reporter assay was performed with the FXRE luciferase reporter in the presence of vehicle, 1  $\mu$ M ACR alone, 1  $\mu$ M GW4064 alone, or the combination of 1  $\mu$ M ACR plus 1  $\mu$ M GW4064. Relative luciferase activity was determined after 24 h. Columns and lines indicate the means and SD of triplicate assays. #:  $P < 0.001$ , \*\*:  $P < 0.05$ .

first evidence that GW4064, a synthetic ligand for FXR, preferentially inhibits the growth of HCC cells compared with Hc normal hepatocytes. This study also clearly indicates that the combination of GW4064 plus ACR, which is expected as a HCC chemopreventive agent [8–10], cause a synergistic inhibition of growth in HLE human HCC cells and that this is associated with the induction of apoptosis. This combination also acted cooperatively to induce the arrest of the cell cycle in the G<sub>0</sub>/G<sub>1</sub> phase and the expression of p21<sup>CIP1</sup> and SHP mRNA, but suppress the expression levels of *c-myc* and cyclin D1 mRNA.

As illustrated in Fig. 7, we presume that the synergism generated by the combination of ACR plus GW4064 is mainly associated

with the enhancement of the FXRE reporter activity. FXR regulates the expression of target genes by binding either as a monomer or as a heterodimer with RXR to the FXRE [13]. Therefore, in the present study, ACR and GW4064 cooperatively enhanced the binding of FXR to the FXRE promoter, thereby enhancing the expression of its target genes (Fig. 7, as indicated by A). Among the FXR target genes, SHP is considered to play a role in the inhibition of cell growth because it is a pivotal cell death receptor that targets the mitochondria, leading to the induction of apoptosis and inhibition of tumor growth [32]. GW4064 suppresses the growth of cancer cells through the activation of FXR targeted genes, including SHP [17,25,30,31]. SHP has also been shown to be a direct negative



**Fig. 7.** A hypothetical schematic representation of the effects of the combination of ACR plus GW4064 on growth inhibition in HCC cells. ACR and GW4064 can bind to their receptors, RXR $\alpha$  and FXR, as ligands, and subsequently activate the FXRE promoter activity (A). ACR and GW4064 also inhibit RXR $\alpha$  phosphorylation, which is involved in liver carcinogenesis, by inhibiting ERK and Stat3 phosphorylation (B). The inhibition of RXR $\alpha$  phosphorylation by these agents might restore the function of this nuclear receptor as a heterodimeric partner for FXR (C), thus resulting in the activation of the FXRE promoter activity. Cooperative activation of this promoter activity by ACR and GW4064 regulates the expression of target genes, such as p21<sup>CIP1</sup>, *c-myc*, cyclin D1, and SHP, which play a critical role in the induction of apoptosis, control of cell cycle progression, and inhibition of cancer cell growth (D). For additional details see Section 4.

regulator of cyclin D1 gene transcription [30]. Treatment with 1  $\mu$ M GW4064 alone did not significantly increase the expression levels of SHP mRNA in the present study, whereas its expression was clearly increased by combined treatment with ACR plus GW4064. These findings may indicate that the concentration of 1  $\mu$ M is insufficient to increase the levels of SHP mRNA in HCC cells and, therefore, an appropriate partner, such as ACR, is required for GW4064 to exert a synergistic effect on growth inhibition in HCC cells (Fig. 7).

In addition, recent studies have revealed that activating FXR suppresses the expression of cyclin D1 and *c-myc*, but induces the expression of p21<sup>CIP1</sup>, by targeting the Wnt/ $\beta$ -catenin signaling pathway [17,31]. These findings seem to be significant because the Wnt/ $\beta$ -catenin pathway plays a critical role in liver carcinogenesis, and thus may be a promising target for the treatment of HCC [33]. In FXR knockout mice, sustained activation of this pathway was shown to be involved in the development of HCC [17]. On the other hand, ACR has been shown to exert growth inhibitory effects in HCC cells by targeting the Wnt/ $\beta$ -catenin pathway [12]. ACR also induces apoptosis and cell cycle arrest in the G<sub>0</sub>/G<sub>1</sub> phase in HCC cells by regulating the expression of p21<sup>CIP1</sup>, cyclin D1, and *c-myc* [12,19,34,35]. Therefore, the activation of FXR by GW4064 may act cooperatively with ACR to inhibit the activation of the Wnt/ $\beta$ -catenin pathway, subsequently decreasing the expression of cyclin D1 and *c-myc*, but increasing the expression of p21<sup>CIP1</sup>, as was demonstrated in the present study.

In addition to chronic inflammation and subsequent cirrhosis of the liver induced by persistent infection with hepatitis virus, increased evidence has indicated that a malfunction of RXR $\alpha$  due to phosphorylation is profoundly involved in the development of HCC [4–8]. In HCC cells, the Ras/MAPK signaling pathway is highly activated, leading to phosphorylation of RXR $\alpha$ , which indicates that the Ras/MAPK pathway and p-RXR $\alpha$  are potential targets for inhibiting the growth of HCC cells [4–8]. Indeed, ACR dephosphorylates RXR $\alpha$ , ERK, and Stat3 proteins, and restores the function of RXR $\alpha$ , thus inhibiting the growth of HCC cells and suppressing liver tumorigenesis in obese mice [4,11,20,36]. The combinations of ACR plus valproic acid or vitamin K<sub>2</sub> also synergistically

suppressed the growth of HCC cells by inhibiting RXR $\alpha$  phosphorylation [11,20]. Similar to these previous studies [11,20], in the present study, inhibition of RXR $\alpha$  phosphorylation by the combination of ACR plus GW4064 may also have restored the function of RXR $\alpha$  as a master regulator of nuclear receptors, thus contributing to synergistic growth inhibition in HCC cells (Fig. 7, as indicated by B). Dephosphorylation of RXR $\alpha$  by this combination treatment may play a role in the observed enhancement of the FXRE promoter activity because phosphorylation of RXR $\alpha$  abolishes its ability to form heterodimers with other nuclear receptors, but inhibition of this phosphorylation can restore its heterodimeric activity [7]. The combination of ACR plus GW4064 may also promote RXRs homodimerization and thus enhance the promoter activity of retinoid X response element, which is associated with the anticancer mechanisms of ACR [11,37].

One of the major questions that arose was how the combination of ACR plus GW4064 could inhibit the phosphorylation of ERK and Stat3 proteins. One of the mechanisms which might explain this phenomenon is that the effects of ACR and GW4064 inhibit the activation of specific receptor tyrosine kinases (RTKs). ACR has been shown to reduce HCC development and inhibit cancer growth by targeting growth factors and their corresponding RTKs, such as the epidermal growth factor (EGF) receptor (EGFR), and downstream signaling pathways, including the Ras/MAPK and Jak/Stat3 pathways [29,38]. The activation of FXR by its ligand also reduces the expression of HER2, a member of the EGFR family of RTKs, and inhibits EGF-mediated HER2 and ERK phosphorylation in human breast cancer cells [24]. Therefore, GW4064 may increase the inhibitory effects of ACR on certain types of RTKs by activating FXR, which results in the inhibition of ERK and Stat3 phosphorylation and subsequent RXR $\alpha$  phosphorylation. Future studies are required to clarify whether both ACR and GW4064 synergistically exert inhibitory effects on the activation of specific RTKs.

Finally, it should be noted that, in a clinical trial showing the chemopreventive effects of ACR on the recurrence of secondary HCC [9,10], the plasma concentration of this agent (which ranged from 1 to 5  $\mu$ M) was approximately the same as the concentration used in the present study (1  $\mu$ M). In phase II clinical trials, a FXR

ligand also ameliorated the increase in the alkaline phosphatase levels in patients with primary biliary cirrhosis and improved the insulin sensitivity in patients with diabetes and liver steatosis, although some unfavorable events that might be associated with FXRE reporter overactivity were observed [39]. The combination of ACR plus GW4064 may resolve such problems because this combination permits the administration of lower doses of both agents for treatment. Future pharmacokinetic studies are required to determine whether the dose of GW4064 used in this study is clinically relevant and pilot studies confirming are thus called for to clarify the safety of this agent.

In conclusion, the observation that a combination of appropriate concentrations of ACR plus GW4064 can inhibit the growth of human HCC cells without affecting the growth of normal hepatocytes should encourage further clinical studies using these agents to investigate their potential for HCC chemoprevention and chemotherapy. The results of our present study suggest that combining ACR with GW4064 might hold promise as a clinical modality for the prevention and treatment of HCC, due to their synergistic effects.

## References

- [1] D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, R.M. Evans, The nuclear receptor superfamily: the second decade, *Cell* 83 (1995) 835–839.
- [2] P. Chambon, A decade of molecular biology of retinoic acid receptors, *Faseb. J.* 10 (1996) 940–954.
- [3] L. Altucci, M.D. Leibowitz, K.M. Ogilvie, A.R. de Lera, H. Gronemeyer, RAR and RXR modulation in cancer and metabolic disease, *Nat. Rev. Drug Discov.* 6 (2007) 793–810.
- [4] R. Matsushima-Nishiwaki, M. Okuno, Y. Takano, S. Kojima, S.L. Friedman, H. Moriwaki, Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid, *Carcinogenesis* 24 (2003) 1353–1359.
- [5] R. Matsushima-Nishiwaki, M. Okuno, S. Adachi, T. Sano, K. Akita, H. Moriwaki, S.L. Friedman, S. Kojima, Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma, *Cancer Res.* 61 (2001) 7675–7682.
- [6] S. Adachi, M. Okuno, R. Matsushima-Nishiwaki, Y. Takano, S. Kojima, S.L. Friedman, H. Moriwaki, Y. Okano, Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma, *Hepatology* 35 (2002) 332–340.
- [7] K. Yoshimura, Y. Muto, M. Shimizu, R. Matsushima-Nishiwaki, M. Okuno, Y. Takano, H. Tsurumi, S. Kojima, Y. Okano, H. Moriwaki, Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta, *Cancer Sci.* 98 (2007) 1868–1874.
- [8] M. Shimizu, K. Takai, H. Moriwaki, Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention, *Cancer Sci.* 100 (2009) 369–374.
- [9] Y. Muto, H. Moriwaki, M. Ninomiya, S. Adachi, A. Saito, K.T. Takasaki, T. Tanaka, K. Tsurumi, M. Okuno, E. Tomita, T. Nakamura, T. Kojima, Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma prevention study group, *New Engl. J. Med.* 334 (1996) 1561–1567.
- [10] Y. Muto, H. Moriwaki, A. Saito, Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma, *New Engl. J. Med.* 340 (1999) 1046–1047.
- [11] H. Tatebe, M. Shimizu, Y. Shirakami, H. Sakai, Y. Yasuda, H. Tsurumi, H. Moriwaki, Acyclic retinoid synergizes with valproic acid to inhibit growth in human hepatocellular carcinoma cells, *Cancer Lett.* 285 (2009) 210–217.
- [12] M. Suzui, M. Masuda, J.T. Lim, C. Albanese, R.G. Pestell, I.B. Weinstein, Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1, *Cancer Res.* 62 (2002) 3997–4006.
- [13] Y.D. Wang, W.D. Chen, D.D. Moore, W. Huang, FXR: a metabolic regulator and cell protector, *Cell Res.* 18 (2008) 1087–1095.
- [14] W. Huang, K. Ma, J. Zhang, M. Qatanani, J. Cuvillier, J. Liu, B. Dong, X. Huang, D.D. Moore, Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration, *Science* 312 (2006) 233–236.
- [15] F. Yang, X. Huang, T. Yi, Y. Yen, D.D. Moore, W. Huang, Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor, *Cancer Res.* 67 (2007) 863–867.
- [16] I. Kim, K. Morimura, Y. Shah, Q. Yang, J.M. Ward, F.J. Gonzalez, Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice, *Carcinogenesis* 28 (2007) 940–946.
- [17] A. Wolfe, A. Thomas, G. Edwards, R. Jaseja, G.L. Guo, U. Apte, Increased activation of the Wnt/(beta)-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice, *J. Pharmacol. Exp. Ther.* 338 (2011) 12–21.
- [18] A. Obora, Y. Shiratori, M. Okuno, S. Adachi, Y. Takano, R. Matsushima-Nishiwaki, I. Yasuda, Y. Yamada, K. Akita, T. Sano, J. Shimada, S. Kojima, Y. Okano, S.L. Friedman, H. Moriwaki, Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells, *Hepatology* 36 (2002) 1115–1124.
- [19] M. Shimizu, M. Suzui, A. Deguchi, J.T. Lim, D. Xiao, J.H. Hayes, K.P. Papadopoulos, I.B. Weinstein, Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells, *Clin. Cancer Res.* 10 (2004) 6710–6721.
- [20] T. Kanamori, M. Shimizu, M. Okuno, R. Matsushima-Nishiwaki, H. Tsurumi, S. Kojima, H. Moriwaki, Synergistic growth inhibition by acyclic retinoid and vitamin K<sub>2</sub> in human hepatocellular carcinoma cells, *Cancer Sci.* 98 (2007) 431–437.
- [21] H. Tatebe, M. Shimizu, Y. Shirakami, H. Tsurumi, H. Moriwaki, Synergistic growth inhibition by 9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells, *Clin. Cancer Res.* 14 (2008) 2806–2812.
- [22] Y. Liu, Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis, *J. Clin. Invest.* 112 (2003) 1678–1687.
- [23] I. Kim, S.H. Ahn, T. Inagaki, M. Choi, S. Ito, G.L. Guo, S.A. Kliewer, F.J. Gonzalez, Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine, *J. Lipid Res.* 48 (2007) 2664–2672.
- [24] C. Giordano, S. Catalano, S. Panza, D. Vizza, I. Barone, D. Bonfiglio, L. Gelsomino, P. Rizza, S.A. Fuqua, S. Ando, Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression, *Oncogene* (2011).
- [25] K.E. Swales, M. Korbonits, R. Carpenter, D.T. Walsh, T.D. Warner, D. Bishop-Bailey, The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression, *Cancer Res.* 66 (2006) 10120–10126.
- [26] J. Kaeding, E. Bouchaert, J. Belanger, P. Caron, S. Chouinard, M. Verreault, O. Larouche, G. Pelletier, B. Stael, A. Belanger, O. Barbier, Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells, *Biochem. J.* 410 (2008) 245–253.
- [27] L. Zhao, M.G. Wientjes, J.L. Au, Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses, *Clin. Cancer Res.* 10 (2004) 7994–8004.
- [28] M. Shimizu, Y. Yasuda, H. Sakai, M. Kubota, D. Terakura, A. Baba, T. Ohno, T. Kochi, H. Tsurumi, T. Tanaka, H. Moriwaki, Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice, *BMC Cancer* 11 (2011) 281.
- [29] M. Shimizu, M. Suzui, A. Deguchi, J.T. Lim, I.B. Weinstein, Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells, *Clin. Cancer Res.* 10 (2004) 1130–1140.
- [30] Y. Zhang, P. Xu, K. Park, Y. Choi, D.D. Moore, L. Wang, Orphan receptor small heterodimer partner suppresses tumorigenesis by modulating cyclin D1 expression and cellular proliferation, *Hepatology* 48 (2008) 289–298.
- [31] R.R. Maran, A. Thomas, M. Roth, Z. Sheng, N. Esterly, D. Pinson, X. Gao, Y. Zhang, V. Ganapathy, F.J. Gonzalez, G.L. Guo, Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development, *J. Pharmacol. Exp. Ther.* 328 (2009) 469–477.
- [32] Y. Zhang, J. Soto, K. Park, G. Viswanath, S. Kuwada, E.D. Abel, L. Wang, Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth, *Mol. Cell Biol.* 30 (2010) 1341–1356.
- [33] D.J. Mulholland, S. Dedhar, G.A. Coetzee, C.C. Nelson, Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?, *Endocr Rev.* 26 (2005) 898–915.
- [34] Y. Yamada, Y. Shidoji, Y. Fukutomi, T. Ishikawa, T. Kaneko, H. Nakagawa, M. Imawari, H. Moriwaki, Y. Muto, Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines, *Mol. Carcinog.* 10 (1994) 151–158.
- [35] M. Suzui, M. Shimizu, M. Masuda, J.T. Lim, N. Yoshimi, I.B. Weinstein, Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells, *Mol. Cancer Ther.* 3 (2004) 309–316.
- [36] M. Shimizu, H. Sakai, Y. Shirakami, J. Iwasa, Y. Yasuda, M. Kubota, K. Takai, H. Tsurumi, T. Tanaka, H. Moriwaki, Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKSJ-*+/db*+/*Lepr*(*db*) mice, *Cancer Prev. Res.* 4 (2011) 128–136.
- [37] H. Araki, Y. Shidoji, Y. Yamada, H. Moriwaki, Y. Muto, Retinoid agonist activities of synthetic geranyl geranoic acid derivatives, *Biochem. Biophys. Res. Commun.* 209 (1995) 66–72.
- [38] T. Sano, M. Kagawa, M. Okuno, N. Ishibashi, M. Hashimoto, M. Yamamoto, R. Suzuki, H. Kohno, R. Matsushima-Nishiwaki, Y. Takano, H. Tsurumi, S. Kojima, S.L. Friedman, H. Moriwaki, T. Tanaka, Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells, *Nutr. Cancer* 51 (2005) 197–206.
- [39] S. Fiorucci, S. Cipriani, A. Mencarelli, F. Baldelli, G. Bifulco, A. Zampella, Farnesoid X Receptor Agonist for the Treatment of Liver and Metabolic Disorders: Focus on 6-ethyl-CDCA, *Mini Rev. Med. Chem.* 11 (2011) 753–762.

**Special Report**

# Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma

Kazuyuki Suzuki,<sup>1</sup> Ryujin Endo,<sup>1</sup> Yutaka Kohgo,<sup>3</sup> Takaaki Ohtake,<sup>3</sup> Yoshiyuki Ueno,<sup>4</sup> Akinobu Kato,<sup>2</sup> Kazutomo Suzuki,<sup>5</sup> Ryo Shiraki,<sup>6</sup> Hisataka Moriawaki,<sup>6</sup> Daiki Habu,<sup>7</sup> Masaki Saito,<sup>9</sup> Shuhei Nishiguchi,<sup>9</sup> Kazuhiro Katayama,<sup>8</sup> Isao Sakaida<sup>10</sup> and for the Japanese Nutritional Study Group for Liver Cirrhosis 2008\*

<sup>1</sup>Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, <sup>2</sup>Morioka Municipal Hospital, Iwate, <sup>3</sup>Division of Gastroenterology and Hepatology/Oncology, Department of Medicine, Hokkaido Medical University, Hokkaido, <sup>4</sup>Division of Gastroenterology, Tohoku University Graduate School of Medicine, Miyagi, <sup>5</sup>Department of Gastroenterology and Hepatology, Koshigaya Hospital, Dokkyo Medical University, Saitama, <sup>6</sup>Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu, <sup>7</sup>Department of Food and Human Health Science, Graduate School of Human Life Science, Osaka City University, <sup>8</sup>Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular diseases, Osaka, <sup>9</sup>Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, and <sup>10</sup>Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

**Aim:** The Japanese Nutritional Study Group for Liver Cirrhosis (JNUS) was assembled in 2008 with the support of a Health Labor Sciences Research Grant from the Ministry of Health, Labor and Welfare of Japan. The goal of the study group was to propose new nutritional guidelines for Japanese patients with liver cirrhosis (LC), with the aim of preventing hepatocellular carcinoma.

**Methods:** Between 2008 and 2010, the member investigators of JNUS conducted various clinical and experimental studies on nutrition on LC. These included anthropometric studies, a questionnaire study on daily nutrient intake, clinical trials, experimental studies using animal models, re-evaluation of previous publications and patient education. Over this 3-year period, the group members regularly discussed the nutritional issues related to LC, and a proposal was finally produced.

**Results:** Based on the results of JNUS projects and discussions among the members, general recommendations were made on how Japanese patients with LC should be managed nutritionally. These recommendations were proposed with a specific regard to the prevention of hepatocarcinogenesis.

**Conclusion:** The new JNUS guidelines on nutritional management for Japanese patients with LC will be useful for the actual nutritional management of patients with LC. The JNUS members hope that these guidelines will form the basis for future discussions and provide some direction in nutritional studies in the field of hepatology.

**Key words:** hepatocellular carcinoma, liver cirrhosis, malnutrition, nutrition, protein-energy malnutrition

*Correspondence:* Dr Kazuyuki Suzuki, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, Iwate 020-8505, Japan. Email: kasuzuki@iwate-med.ac.jp

\*Collaborators in the JNUS group: Naohiro Kawamura (The Third Department of Internal Medicine, Kyorin University), Koichi Shiraishi (Division of Gastroenterology, Department of Internal Medicine, Tokai University), Masahiko Kato (School of Life Science, Sugiyama Jogakuin University), Motoh Iwasa (Department of Gastroenterology and Hepatology, Mie University), Kazuho Imanaka (Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Disease), Toshinori Ito (Department of Medicine, Osaka Koseinenkin Hospital), Makoto Kuboki (Department of Gastroenterology, Hepatology and Nutrition, Kurashiki Medical Center), Yoshio Tokumoto (Department of Gastroenterology and Metabolism, Ehime University) and Takumi Kawaguchi (Department of Digestive Disease Information and Research, Kurume University).

Received 26 December 2011; revised 13 February 2012; accepted 16 February 2012.

## INTRODUCTION

THE LIVER IS a major organ in nutritional metabolism. Therefore, metabolic abnormalities in nutritional elements are generally observed in the progression of chronic liver disease (CLD). Malnutrition, which is characterized by protein-energy malnutrition (PEM), is known as an essential complication in patients with liver cirrhosis (LC) and is closely associated with LC prognosis.<sup>1–7</sup> On the other hand, the major cause of CLD in Japan is infection by hepatitis B virus (HBV) and hepatitis C virus (HCV) and approximately 34 000 patients with CLD die annually due to hepatocellular carcinoma (HCC).<sup>8–11</sup> Importantly, 90% of HCC cases are associated with LC.<sup>12,13</sup> Therefore, standard therapeutic guidelines on the use of antiviral agents for CLD patients with HBV and HCV infection have been established to prevent the occurrence of HCC.<sup>14,15</sup> However, because the number of elderly CLD patients is increasing, patients are often unable to tolerate full antiviral therapy. CLD caused by non-alcoholic steatohepatitis (NASH), which is associated with overweight status, has also been increasing.<sup>16–18</sup> These findings indicate that total nutritional management, including both diet and nutritional supplements, is required in order to prevent the progression of CLD and onset of HCC.<sup>19–22</sup>

Japanese dietitians were consulted in preparing the guidelines of both the Japan Society of Metabolism and Clinical Nutrition (2003)<sup>23</sup> and the European Society of Parenteral and Enteral Nutrition (2006 and 2009).<sup>24,25</sup> In addition, nutritional recommendations for the treatment of LC in Japan were incorporated into guidelines in Japan in 2010.<sup>26</sup> However, specific and detailed guidelines for the nutritional management of patients with LC in Japan have been lacking.

From these perspectives, the Japanese Nutritional Study Group for Liver Cirrhosis (JNUS) was assembled between 2008 and 2010 in order to establish new nutritional guidelines for LC. The study group was supported by a Health Labor Sciences Research Grant from the Ministry of Health, Labor and Welfare of Japan (H20-Hepatitis-General-005). Here, we describe the guidelines on nutritional management of Japanese LC patients, with the aim of preventing HCC.

## METHODS

THE JNUS GROUP performed the following projects: (i) investigation of clinical and anthropometric characteristics in Japanese patients with LC; (ii) evaluation of daily nutrient intake (total calories, and

individual intake of protein, fat, carbohydrate, trace elements such as iron and zinc, and sodium) using a 3-day questionnaire in CLD patients; (iii) development of new biomarkers representing non-protein respiratory quotients (npRQ) measured by indirect calorimetry; (iv) development of a new analytical system to estimate iron status in the blood; (v) a prospective controlled trial to examine whether branched-chain amino acid (BCAA) granule supplementation prevents recurrence of HCC after primary HCC treatment; (vi) a prospective double-blind controlled study evaluating the effects of zinc supplementation on the ammonia metabolism in LC patients with hyperammonemia; (vii) a pilot study to evaluate the effects of late-evening snacks (LES) and a new treatment ( $\alpha$ -glucosidase inhibitor) in LC patients with impaired glucose tolerance; (viii) an experimental study to estimate the effects of supplementation of BCAA granules on the development of HCC in a mouse model of NASH; (ix) education programs for nutritional management in both LC patients and the general Japanese population; and (x) re-evaluation of previous publications concerning nutritional therapies in LC patients. After repeated discussion of the results, we then proposed the new guidelines for nutritional management of Japanese LC patients with the aim of preventing HCC.

## RESULTS

THE FOLLOWING FINDINGS were obtained: (i) approximately 30% of patients with LC are overweight (body mass index >25), with the incidence being higher in male LC patients due to NASH and alcohol; (ii) only 30% of LC patients have adequate dietary intake for both energy and protein; (iii) iron intake (mean value, 6.7 mg/day) does not differ among CLD patients; (iv) percent arm circumference, percent arm muscle circumference, and serum concentrations of free fatty acid, tumor necrosis factor (TNF)- $\alpha$  and soluble TNF receptors are significantly correlated with npRQ;<sup>27–29</sup> (v) serum non-transferrin-bound iron (NTBI) determined by a newly developed high-performance liquid chromatography system is elevated in LC patients,<sup>30,31</sup> although further study is necessary to clarify whether serum NTBI levels are associated with the development of HCC; (vi) plasma amino acid imbalance is closely associated with the numbers and functions of peripheral dendritic cells;<sup>32</sup> (vii) long-term zinc supplementation therapy in LC patients tends to decrease HCC occurrence; (viii) LES and administration of  $\alpha$ -glucosidase inhibitor improve impaired glucose